Evaluation of small extracellular vesicles derived miRNA as biomarkers for Parkinson’s disease: comparison with plasma miRNA
Objective: To identify differentially expressed small extracellular vesicles (sEV) derived miRNAs in Parkinson’s disease using small RNA-sequencing and to evaluate their potential as biomarker targets.…IP-RT-QuIC Identify Disease-Specific Alpha-Synuclein Seeds in serum from patients with syncleinopathy
Objective: To examine whether alpha-synuclein (aSyn) seed exists in the serum and its potential as a serum biomarker. Background: Parkinson’s disease (PD) and Multiple system…Glucocerebrosidase (GCase) activator, Ambroxol, reduces alpha-synuclein serine-129 phosphorylation and oligomers in mutant LRRK2 R1441G mouse brains
Objective: To explore whether inducing brain GCase activity by Ambroxol™ (ABX; a brain-penetrant GCase activator) can reduce a-synuclein (αSyn) serine-129 phosphorylation and oligomer accumulation in…Lysosomal-driven reduction of alpha-synuclein aggregates in a neuron-like model of Parkinson’s disease
Objective: To test whether PIKfyve inhibition results in a lysosomal-driven reduction of alpha-synuclein aggregates in a mutant neuroblastoma cell line overexpressing an aggregation-prone form of…SLP-2 modulated expression rescues mitochondrial function in alpha-synuclein neuropathology models
Objective: Validate the rescue potential of SLP-2 induction for α-synuclein (aSyn)-induced mitochondrial pathology and neurodegeneration in two complementary models: human induced pluripotent stem cell (hiPSC)-derived…The Role of Adaptive Immunity caused by α-synuclein Recognition Specific Sequence Peptide on the Onset of Parkinson’s Disease Pathogenesis
Objective: We investigated whether α-synuclein-derived peptides (recognized specific sequence in α-synuclein) can drive T-cell response and evaluated the neurotoxicity of α-synuclein peptide-specific T-cell in Parkinson’s…Characterization of the pathogenic α-Synuclein variant p.V15A in Parkinson´s disease
Objective: To investigate functional alterations of the p.V15A variant in alpha-Synuclein (α-Syn) in Parkinson's disease (PD). Background: PD is marked by the loss of dopaminergic…The role of the glymphatic system on the severity and distribution of alpha-synuclein pathology in alpha-synuclein fibril induced rat model of Parkinson’s disease
Objective: The aim of this study is to investigate the contribution of the glymphatic system to the pathophysiology of Parkinson's disease (PD). Background: Neurotoxicity of…PASADENA 1-year open-label extension
Objective: To describe the results of PASADENA 1-year open-label extension (OLE). Background: Prasinezumab is a humanized monoclonal antibody that binds aggregated alpha-synuclein with the potential…An SNCA triplication in a Kazakhstani patient with young-onset Parkinson’s disease
Objective: To report a patient with Parkinson’s disease (PD) from Kazakhstan with a rare structural defect in the SNCA gene. Background: Little is known about…
- « Previous Page
- 1
- …
- 19
- 20
- 21
- 22
- 23
- …
- 60
- Next Page »